A new report from Prophecy Market Insights (PMI) reveals that the cell and gene therapy CDMO market is expected to reach $18.6 billion by 2032.
According to the report, new partnerships with pharmaceutical and biotechnology companies have enabled CDMO players to fuel the rapid growth of capabilities and capacities by helping industries succeed in drug and vaccine production. Integration of clinical trial services is expected to become a new trend for CDMOs as they enter high-value, low-volume segments such as personalized medicine.
